TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03595059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-155
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-155
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-155
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-155
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-155
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous (IV) Infusion
Study: NCT03760744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CDT with Negative Pressure
Description: Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CDT alone
Description: Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
Study: NCT00401518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Randomized ACADIA® Facet Replacement System
Description: Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Instrumented posterolateral fusion (PLF)
Description: Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
Study: NCT02721498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)
Description: An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest period
Description: A 30-60 minute of resting
Study: NCT02417857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy (Single Incision)
Description: We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy (Conventional)
Description: We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
Study: NCT02590237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu KingVision Video Laryngoscope aBlade
Description: At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Direct Laryngoscopy
Description: At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
Study: NCT02714010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiotherapy
Description: 30Gy/10F
Study: NCT04568798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sana Sham Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study: NCT04745169

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8 week home-based exercise program
Description: Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
Study: NCT03073941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona total knee system
Description: 314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexgen total knee system
Description: 314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
Study: NCT04568798

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sana Sham Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study: NCT01738529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLE ileocolonoscopy
Description: The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CLE ileocolonoscopy
Description: The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
Study: NCT03193333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-122
Description: Posology: 1 drop every 12 hours for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol eye drops
Description: 1 drop every 12 hours for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide-Timolol Ophthalmic
Description: 1 drop every 12 hours for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Ophthalmic Solution
Description: 1 drop every 12 hours for 90 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo1
Description: 1 drop of each dropper bottle every 12 hours for 90 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo1
Description: 1 drop of each dropper bottle every 12 hours for 90 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: 1 drop of each dropper bottle every 12 hours for 90 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 2
Description: 1 drop of each dropper bottle every 12 hours for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Krytantek
Description: Posology: 1 drop every 12 hours for 90 days
Study: NCT01827592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Description: Elobixibat 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg
Description: Elobixibat 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04036591

Intervention type: DIAGNOSTIC_TEST
Intervention: Acute Bronchiolitis Severity Scale (ABSS)
Description: All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
Study: NCT04639362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib, venetoclax, obinutuzumab
Description: Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib, venetoclax
Description: Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
Study: NCT03520712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene Roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study: NCT01034228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORS + Isoleucine
Description: ORS with Isolelucine for treatment of diarrhoeal in children

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ORS without Isoleucine
Description: ORS without Isoleucine for the treatment of diarrhoea in children
Study: NCT04296578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily
Study: NCT06784739

Intervention type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling
Study: NCT04296578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily
Study: NCT04468724

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MAKASI
Description: The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAKASI
Description: The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons.
Study: NCT03448523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right To Play's Positive Child and Youth Development program
Description: 1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection
Study: NCT00684164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D5
Description: Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
Study: NCT06784739

Intervention type: OTHER
Intervention: Mucosal sampling
Description: Saliva and nasal secretions

Intervention type: OTHER
Intervention: Mucosal sampling
Description: Saliva and nasal secretions

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR-test
Description: RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR-test
Description: RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
Study: NCT06785077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal cells
Description: custom myeloid gene panel (Myelo-Panel) to identify germline mutations predisposing to cancer development (Thermo Fisher Scientific)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow cells
Description: Bone marrow cells (optional, for comparison, only in a limited number of patients):~* morphological analysis~* immunophenotype~* cytogenetics/FISH~* analysis of CHIP by custom gene panel and high sensitivity NGS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood cells
Description: analysis of CHIP by custom gene panel and high sensitivity NGS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow biopsy
Description: Bone marrow biopsy (optional, for comparison, only in a limited number of patients):~* histology~* immunohistochemistry
Study: NCT03206827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 70% animal, 30% plant proteins in diet
Description: Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% animal, 50% plant proteins in diet
Description: Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% animal, 70% plant proteins in diet
Description: Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
Study: NCT01039779

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
Study: NCT01353391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Study: NCT04823390

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam-Fentanyl combination
Description: Sedation is given to patients undergoing cataract surgery under local anesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam-Fentanyl combination
Description: Sedation is given to patients undergoing cataract surgery under local anesthesia
Study: NCT03491787

Intervention type: DEVICE
Intervention: Ultrasound guidance
Description: The ultrasound guidance was used to obtain intraosseous access
Study: NCT03446118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI to detect inflammation and fibrosis in subjects with EoE
Description: MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
Study: NCT03470454

Intervention type: DRUG
Intervention: Linagliptin Oral Tablet
Description: Linagliptin for blood glucose control

Intervention type: DRUG
Intervention: Linagliptin Oral Tablet
Description: Linagliptin for blood glucose control
Study: NCT06787027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage technique
Description: Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage technique
Description: Following the morning surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment group
Description: patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment group
Description: patients were prescribed antibiotics (amoxicillin with clavulanic acid, 1 g, twice daily), analgesics (paracetamol, 500 mg, twice daily), and mouthwash (chlorhexidine gluconate, three times daily) for five days. Cold application was recommended to all patients.
Study: NCT01853748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine